Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form.
• People who have been diagnosed with a type of blood cancer called CLL (Chronic Lymphocytic Leukaemia) or SLL (Small Lymphocytic Lymphoma), confirmed using standard 2018 diagnostic guidelines.
• People who previously received a first course of treatment combining two specific types of targeted therapy drugs (a BTK inhibitor and a BCL2 inhibitor, with or without a third drug called obinutuzumab), where that treatment was given for a fixed period of time, the cancer responded well (at least a partial response), and at least 2 years have passed since that treatment ended.
• People for whom certain genetic test results are available or can be obtained before the trial begins, covering three specific markers related to the cancer's biology (IGHV mutation status, deletion of chromosome 17p, and TP53 mutation status).
• People whose general physical health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale (ECOG score of 0, 1, or 2).
• People whose liver, kidneys, and bone marrow are functioning at an adequate level.

Who may not be able to join:

• People with other significant health conditions that, in the treating doctor's opinion, would make participation unsuitable.
• People with serious heart or stroke-related conditions.
• People who are currently bleeding, or who have a history of bleeding disorders (such as haemophilia or von Willebrand disease).
• People with moderate to severe liver cirrhosis (classified as Child-Pugh B or C).
• People who have a history of another cancer, either in the past or currently.
• People who are HIV positive.
• People who have a history of a serious brain condition called Progressive Multifocal Leukoencephalopathy (PML) (confirm with trial site).
• People with a currently active Hepatitis B or Hepatitis C infection.
• People who have been taking steroid medications above a certain dose (more than 20 mg) in the week before the first trial treatment dose.
• People who have previously had a severe allergic reaction to any of the medications used in this trial.
• People who need to take certain medications that strongly interact with a liver enzyme called CYP3A4, as these can affect how trial drugs work in the body (confirm specific medications with trial site).
• People who are taking blood-thinning medications such as warfarin or similar drugs from the same class.
• People who have had a major surgical procedure within 30 days before the first trial treatment dose.

Important: Always verify eligibility with the trial site directly before applying.